Fecal incontinence (FI) is a distressing symptom that substantially impairs quality of life and requires management tailored to its cause and severity. Since the publication of the 2017 edition of the Japanese Practice Guidelines for Fecal Incontinence, awareness and clinical implementation have progressively expanded. The revised second edition was released in November 2024. This review outlines the current diagnosis and treatment for FI, with reference to key updates in the 2024 guidelines.
FI is defined as involuntary loss of feces through the anus, either unconsciously or against one's will. In Japan, its prevalence is approximately 4.0% in adults aged 20–65 years and 7.5% in those over 65. Contributing pathophysiological factors include stool consistency; the function of defecation-related musculature; anorectal sensory function; rectal pressure, capacity and compliance; colonic function; and cognitive and motor function.
FI symptoms are categorized into passive and urge incontinence. Diagnostic evaluation involves history-taking, digital anorectal examination, anorectal physiological testing, and endoanal ultrasonography.
Management strategies are classified into three tiers: initial treatment, specialized conservative therapy, and surgical intervention. A stepwise approach, commencing with the least invasive modality, is generally recommended.
Initial treatment comprises dietary and lifestyle modification, bowel habit training, skin care, adjustment of oral medications such as laxatives, and pharmacological therapy. Specialized conservative therapies include pelvic floor muscle training, biofeedback therapy, and transanal irrigation. Among surgical options, sacral neuromodulation and sphincteroplasty are regarded as first-line procedures, whereas gastrointestinal stoma creation is considered a second-line intervention. Anal sphincter restoration using regenerative medicine is an emerging area of ongoing research.
View full abstract